• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全基因组杂合性缺失搜索显示人类乳腺癌具有广泛的遗传多样性。

Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas.

作者信息

Kerangueven F, Noguchi T, Coulier F, Allione F, Wargniez V, Simony-Lafontaine J, Longy M, Jacquemier J, Sobol H, Eisinger F, Birnbaum D

机构信息

Laboratoire de Biologie des Tumeurs and CR Inserm 4U003C, Institut Paoli-Calmettes, Marseille, France.

出版信息

Cancer Res. 1997 Dec 15;57(24):5469-74.

PMID:9407952
Abstract

Deletions of genomic regions involving tumor suppressor genes are thought to be important in the initiation and progression of breast cancer. We conducted a genome-wide search for deleted regions in a series of 75 human breast carcinomas by studying the allelic patterns of 184 microsatellite markers distributed over all chromosomes and looking for loss of heterozygosity (LOH). We identified 56 regions of consistent LOH. Strikingly, every tumor had a different set of deletions. To study this complexity, we applied a phylogenetic-like type of analysis. Each region was involved in a certain proportion of tumors, ranging from 20 to 62%; the most frequently involved regions were on chromosome arms 8p, 11q, 16q, and 17p. There was a correlation (P = 0.005) between the level of LOH and the size of the tumors. Tumors with a high level of LOH were also highly proliferative and had a high mitotic index.

摘要

涉及肿瘤抑制基因的基因组区域缺失被认为在乳腺癌的发生和发展中起着重要作用。我们通过研究分布在所有染色体上的184个微卫星标记的等位基因模式并寻找杂合性缺失(LOH),对一系列75例人类乳腺癌进行了全基因组范围的缺失区域搜索。我们确定了56个一致出现杂合性缺失的区域。令人惊讶的是,每个肿瘤都有一组不同的缺失区域。为了研究这种复杂性,我们应用了一种类似系统发育的分析方法。每个区域在一定比例的肿瘤中出现,比例范围从20%到62%;最常出现缺失的区域位于染色体臂8p、11q、16q和17p上。杂合性缺失水平与肿瘤大小之间存在相关性(P = 0.005)。杂合性缺失水平高的肿瘤增殖性也很高,且有高有丝分裂指数。

相似文献

1
Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas.全基因组杂合性缺失搜索显示人类乳腺癌具有广泛的遗传多样性。
Cancer Res. 1997 Dec 15;57(24):5469-74.
2
Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status.宫颈癌中的基因组改变:染色体杂合性缺失与人乳头瘤病毒肿瘤状态
Cancer Res. 1996 Jan 1;56(1):197-205.
3
Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis.利用激光捕获显微切割的乳腺癌组织进行全基因组杂合性缺失检测:对突变体表型和乳腺癌发病机制的启示
Cancer Res. 2000 Jul 15;60(14):3884-92.
4
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.肺癌的全基因组等位基因分型确定了新的等位基因缺失区域、小细胞肺癌与非小细胞肺癌之间的差异以及基因座聚类。
Cancer Res. 2000 Sep 1;60(17):4894-906.
5
Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.1280例乳腺癌的联合研究:17号染色体上等位基因缺失靶向与家族史和临床参数相关的亚区域。
Cancer Res. 1998 Mar 1;58(5):1004-12.
6
Alterations of the 16q22.1 and 16q24.3 chromosomal loci in sporadic invasive breast carcinomas: correlation with proliferative activity, ploidy and hormonal status of the tumors.散发性浸润性乳腺癌中16q22.1和16q24.3染色体位点的改变:与肿瘤增殖活性、倍体及激素状态的相关性
Anticancer Res. 2001 Mar-Apr;21(2A):991-9.
7
High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity.乳腺癌的高分辨率19p13.2 - 13.3等位基因分型显示杂合性频繁缺失。
Genes Chromosomes Cancer. 2004 Nov;41(3):250-6. doi: 10.1002/gcc.20080.
8
Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions.人类乳腺癌中共济失调毛细血管扩张症、考登病和BRCA1基因区域杂合性缺失。
Oncogene. 1997 Jan 23;14(3):339-47. doi: 10.1038/sj.onc.1200818.
9
Localization of a tumor suppressor gene associated with the progression of human breast carcinoma within a 1-cM interval of 8p22-p23.1.与人类乳腺癌进展相关的一个肿瘤抑制基因定位在8号染色体短臂22区至23.1区1厘摩的区间内。
Cancer. 1999 Jan 15;85(2):447-52.
10
Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions.对712例乳腺肿瘤16号染色体长臂进行杂合性缺失定位,揭示了影响候选区域划定的因素。
Cancer Res. 2001 Feb 1;61(3):1171-7.

引用本文的文献

1
The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms.外泌体非编码RNA在乳腺癌耐药中的研究概况,重点关注潜在分子机制。
Front Pharmacol. 2023 Apr 19;14:1152672. doi: 10.3389/fphar.2023.1152672. eCollection 2023.
2
Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity.1型神经纤维瘤病伴杂合性体细胞缺失患者的化生性乳腺癌
Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). doi: 10.1101/mcs.a002352. Print 2018 Apr.
3
MicroRNAs and Their Impact on Breast Cancer, the Tumor Microenvironment, and Disparities.
微小RNA及其对乳腺癌、肿瘤微环境和差异的影响。
Adv Cancer Res. 2017;133:51-76. doi: 10.1016/bs.acr.2016.08.003. Epub 2016 Sep 26.
4
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.细胞外囊泡中的miR-134可降低三阴性乳腺癌的侵袭性并提高药物敏感性。
Oncotarget. 2015 Oct 20;6(32):32774-89. doi: 10.18632/oncotarget.5192.
5
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control.三阴性乳腺癌的综合基因组分析揭示了与临床和分子表型相关的新型微小RNA,并阐明了它们所控制的信号通路。
BMC Genomics. 2013 Sep 23;14:643. doi: 10.1186/1471-2164-14-643.
6
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.原发性乳腺癌患者血液游离肿瘤 DNA 与骨髓中播散肿瘤细胞的比较评估。
Breast Cancer Res. 2009;11(5):R71. doi: 10.1186/bcr2404.
7
Mutational heterogeneity in human cancers: origin and consequences.人类癌症中的突变异质性:起源与后果。
Annu Rev Pathol. 2010;5:51-75. doi: 10.1146/annurev-pathol-121808-102113.
8
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.miRNA 特征可预测乳腺癌中雌激素受体、孕激素受体和 HER2/neu 受体状态。
Breast Cancer Res. 2009;11(3):R27. doi: 10.1186/bcr2257. Epub 2009 May 11.
9
CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer.CDKN1C/p57kip2是人类乳腺癌中的一个候选抑癌基因。
BMC Cancer. 2008 Mar 6;8:68. doi: 10.1186/1471-2407-8-68.
10
Clonal mutations in primary human glial tumors: evidence in support of the mutator hypothesis.原发性人类胶质瘤中的克隆性突变:支持突变体假说的证据。
BMC Cancer. 2007 Oct 9;7:190. doi: 10.1186/1471-2407-7-190.